Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other…
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- NCT00588770
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 779 sites in United States, Puerto Rico and 1 more
- Volunteers
- 403 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Esophageal Squamous Cell Carcinoma
A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
This study is a single-arm, prospective, phase II trial for patients with metastatic esophageal squamous cell carcinoma (ESCC) who received immunotherapy plus chemotherapy as the first-line treatment.
- Trial name
- NCT05760391
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
This clinical trial aims to assess the efficacy of Optical Coherence Tomography (OCT) in the early diagnosis of oral cancer. It focuses on Oral Potentially Malignant Disorders (OPMDs) as precursors to Oral Squamous Cell Carcinoma…
- Conditions
- Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder, Oral Leukoplakia, Proliferative Verrucous Leukoplakia
- Trial name
- SYMILIS OCT (NCT06321003)
- Testing
- OCT (Optical Coherence Tomography)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Palermo
Head and Neck Cancer
Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004246
- Testing
- Fludarabine Phosphate, Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00589186
- Testing
- Ad5F35-LMP1/LMP2-transduced autologous dendritic cells, celecoxib, flow cytometry
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Head and Neck Squamous Cell Carcinoma
The Head and Neck Tumor Biobank
The purpose of the biobank is to enable future genomic based research on this Head and Neck Cancer patient population. The investigators will try to identify tumor factors that will predict cancer-related outcome in order to…
- Trial name
- NCT01644786
- Where
- Netherlands
- Volunteers
- 419 people
- Sponsor
- Maastricht Radiation Oncology
Carcinoma, Squamous Cell of Head and Neck
Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer
The aim of the study is to improve the loco-regional control rate and overall survival of locally advanced head and neck squamous carcinoma (HNSCC).
- Trial name
- NCT00957086
- Testing
- Nimotuzumab
- Where
- 30 sites in Australia, Cuba and 11 more
- Volunteers
- 710 people
- Sponsor
- National Cancer Centre, Singapore
Head and Neck Squamous Cell Carcinoma, Lung Cancer
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
- Trial name
- ABIMMUNE (NCT03212469)
- Testing
- Durvalumab, Tremelimumab, SBRT
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
This phase II trial studies how well sorafenib works with carboplatin and paclitaxel in treating participants with head and neck squamous cell cancer that has spread to other parts of the body or that has come back.
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity
- Trial name
- NCT00494182
- Testing
- Carboplatin, Paclitaxel, Sorafenib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
- Trial name
- NCT05208762
- Testing
- PF-08046054, pembrolizumab
- Where
- 62 sites in United States, Belgium and 9 more
- Volunteers
- 714 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Locally Advanced Head and Neck Squamous Cell Carcinoma
Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Over 60% of head and neck squamous cell carcinoma (HNSCC) patients are diagnosed at a locally advanced stage. While standard treatments involve surgery and chemoradiotherapy, prognosis remains poor, with 50-60% experiencing local…
- Trial name
- NCT07371234
- Testing
- Neoadjuvant and Adjuvant Immunotherapy, Low-dose radiotherapy, Surgery
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Rui You
ESCC
Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive, operator-dependent, and limited in their ability…
- Trial name
- SYNERGY (NCT07266363)
- Testing
- Small RNA sequencing of exo- and cf-miRNAs, RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay), PCR-based validation (SYNERGY assay)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Esophageal Cancer
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00072033
- Testing
- Cisplatin and Docetaxel
- Where
- 9 sites in Switzerland
- Volunteers
- 66 people
- Sponsor
- Swiss Cancer Institute
Uterine Cervical Neoplasms, Squamous Cell Carcinoma
The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial
Cervical cancer remains an important health problem worldwide. Poor tumor oxygenation (hypoxia) is associated with inferior survival in cervical cancer and resistance to radiation treatment.
- Conditions
- Uterine Cervical Neoplasms, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Adenosquamous
- Trial name
- NCT02394652
- Testing
- Metformin, Cisplatin, FAZA
- Where
- 5 sites in Canada
- Volunteers
- 16 people
- Sponsor
- University Health Network, Toronto
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Oropharyngeal Squamous Cell Carcinoma
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating…
- Trial name
- NCT05268614
- Testing
- Radiation therapy, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Florida
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working.
- Trial name
- NCT07403136
- Testing
- Vebrekotuzumab, PD-1 antibody
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Carcinoma, Squamous Cell
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
- Trial name
- NCT02254044
- Testing
- bivatuzumab mertansine
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Squamous Cell Carcinoma, Head and Neck Cancer
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the…
- Trial name
- NCT01161498
- Testing
- Talimogene Laherparepvec, Radiation, Cisplatin
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- BioVex Limited
HNSCC
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
The purpose of this study is to demonstrate that treatment with avelumab in combination with RT-cetuximab is superior to standard of care (SOC) cisplatin-RT and/or to SOC RT-cetuximab alone in terms of progression-free survival…
- Trial name
- REACH (NCT02999087)
- Testing
- Cetuximab, avelumab, Cisplatin
- Where
- France
- Volunteers
- 707 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.